203 related articles for article (PubMed ID: 18811692)
1. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.
Masago K; Fujita S; Hatachi Y; Fukuhara A; Sakuma K; Ichikawa M; Kim YH; Mio T; Mishima M
Cancer Sci; 2008 Nov; 99(11):2295-301. PubMed ID: 18811692
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
3. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Hayama S; Murakami H; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
Cancer Res; 2005 Oct; 65(20):9176-84. PubMed ID: 16230376
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
Rusch V; Baselga J; Cordon-Cardo C; Orazem J; Zaman M; Hoda S; McIntosh J; Kurie J; Dmitrovsky E
Cancer Res; 1993 May; 53(10 Suppl):2379-85. PubMed ID: 7683573
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
Fontanini G; De Laurentiis M; Vignati S; Chinè S; Lucchi M; Silvestri V; Mussi A; De Placido S; Tortora G; Bianco AR; Gullick W; Angeletti CA; Bevilacqua G; Ciardiello F
Clin Cancer Res; 1998 Jan; 4(1):241-9. PubMed ID: 9516978
[TBL] [Abstract][Full Text] [Related]
7. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Addison CL; Ding K; Zhao H; Le Maître A; Goss GD; Seymour L; Tsao MS; Shepherd FA; Bradbury PA
J Clin Oncol; 2010 Dec; 28(36):5247-56. PubMed ID: 21079146
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Okuda C; Mio T; Mishima M
Oncology; 2010; 79(5-6):355-62. PubMed ID: 21430404
[TBL] [Abstract][Full Text] [Related]
9. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Tanaka T; Nagai Y; Miyazawa H; Koyama N; Matsuoka S; Sutani A; Huqun ; Udagawa K; Murayama Y; Nagata M; Shimizu Y; Ikebuchi K; Kanazawa M; Kobayashi K; Hagiwara K
Cancer Sci; 2007 Feb; 98(2):246-52. PubMed ID: 17233841
[TBL] [Abstract][Full Text] [Related]
10. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.
Vollebergh MA; Kappers I; Klomp HM; Buning-Kager JC; Korse CM; Hauptmann M; de Visser KE; van den Heuvel MM; Linn SC
J Thorac Oncol; 2010 Dec; 5(12):1939-48. PubMed ID: 21102259
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
12. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A; Kobayashi K; Usui K; Maemondo M; Okinaga S; Mikami I; Ando M; Yamazaki K; Saijo Y; Gemma A; Miyazawa H; Tanaka T; Ikebuchi K; Nukiwa T; Morita S; Hagiwara K;
J Clin Oncol; 2009 Mar; 27(9):1394-400. PubMed ID: 19224850
[TBL] [Abstract][Full Text] [Related]
13. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
17. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas.
Saeki T; Salomon DS; Johnson GR; Gullick WJ; Mandai K; Yamagami K; Moriwaki S; Tanada M; Takashima S; Tahara E
Jpn J Clin Oncol; 1995 Dec; 25(6):240-9. PubMed ID: 8523820
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
19. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
